Retour
Explorez tous les épisodes du podcast Eyewire News: The Podcast
Plongez dans la liste complète des épisodes de Eyewire News: The Podcast. Chaque épisode est catalogué accompagné de descriptions détaillées, ce qui facilite la recherche et l'exploration de sujets spécifiques. Suivez tous les épisodes de votre podcast préféré et ne manquez aucun contenu pertinent.
| Titre | Date | Durée | |
|---|---|---|---|
| Ophthalmic Executives Provide Company Updates (Part 2 of 2) | 04 Nov 2026 | 00:14:31 | |
Leaders of several ophthalmic companies with a focus on the posterior segment provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Ophthalmic Executives Provide Company Updates (Part 1 of 2) | 28 Oct 2026 | 00:18:51 | |
Leaders of several thalamic companies provide updates on their pipeline and new products in the special edition of Eyewire News the Podcast.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Breaking News From the AAO Annual Meeting in New Orleans (Part 2 of 2) | 22 Oct 2026 | 00:12:30 | |
Eyewire News the Podcast reports on new products and breaking news live from thee American Academy of Ophthalmology meeting in New Orleans.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Breaking News From the AAO Annual Meeting in New Orleans (Part 1 of 2) | 14 Oct 2026 | 00:10:09 | |
Eyewire News the Podcast reports on new products and breaking news live from thee American Academy of Ophthalmology meeting in New Orleans.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Special Report: Potential of Robotic Cataract Surgery | 07 Oct 2026 | 00:09:27 | |
Leaders pioneering fully robotic assisted cataract surgery, discussed the technology and shared their experience treating the first human patients.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Kodiak Plans to Submit BLA for Zenkuda After Phase 3 Data | 30 Sep 2026 | 00:06:37 | |
Kodiak Sciences meets its primary endpoint in a phase 3 trial for its DME drug candidate clearing the way for a regulatory submission; the European Commission approves Roche’s Susvimo for wet AMD; and Merck announces topline results from a pivotal phase 2b/3 trial evaluating two doses of its DME treatment candidate.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Breaking News From the ESCRS Congress in London (Part 2 of 2) | 23 Sep 2026 | 00:08:46 | |
EyewireTV reports on new products and breaking news live from the ESCRS Congress in London.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Breaking News From the ESCRS Congress in London (Part 1 of 2) | 16 Sep 2026 | 00:10:56 | |
EyewireTV reports on new products and breaking news live from the ESCRS Congress in London.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| FDA Accepts Nanoscopes's Optogenetic Gene Therapy BLA | 09 Sep 2026 | 00:04:57 | |
The FDA accepts a biologics license application (BLA) for a first-of-its-kind optogenetic gene therapy for RP; a software upgrade from Heru combines several pretesting assessments into a single guided workflow; and a new FDA-approved overnight orthokeratology lens is launched in the US.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| FDA Sets PDUFA Date for Investigational Glaucoma Eye Drop | 02 Sep 2026 | 00:06:17 | |
The FDA accepts Nicox’s NDA for an investigational glaucoma drop; Bausch + Lomb provides updates on two key investigational therapies for dry eye and ocular surface pain; and Ocugen doses the first patient in a global phase 3 trial of an investigational gene therapy for geographic atrophy (GA).
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| EyePoint Misses Primary Endpoint in Phase 3 Trial But Sees Promise After Analysis | 26 Aug 2026 | 00:05:47 | |
Eyepoint Pharmaceuticals releases key phase 3 data for its wet AMD drug Duravyu; Zeiss receives FDA clearance for a cloud- and browser-based data management solution; and the FDA expands Sight Sciences’ indications for the TearCare System for the treatment of MGD.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Three Major Acquisitions Announced in Ophthalmology | 12 Aug 2026 | 00:05:33 | |
Tarsus Pharmaceuticals enters into a definitive agreement to acquire Alkeus Pharmaceuticals; Harrow acquires dry eye disease nasal spray Tyrvaya from Viatris; and Italy-based Alfasigma enters into a share purchase agreement with Sever Life Sciences to acquire 100% of Nordic Pharma and its subsidiaries.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Biocon Launches Eylea Biosimilar Yesafili | 05 Aug 2026 | 00:04:07 | |
An interchangeable biosimilar to Eylea is launched in the US; patient enrollment is completed in two global phase 3 clinical trials evaluating Duravyu for diabetic macular edema; and Topcon receives CE mark for a fully automated ultra-widefield retinal slit scanner.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| FDA Approves Outlook's Lytenava for Wet AMD | 29 Jul 2026 | 00:11:55 | |
The CEO of Outlook Therapeutics discusses the FDA approval of wet AMD drug Lytenava; Roche receives a major boost in its efforts to commercialize wet AMD treatment Susvimo in Europe; and Glaukos reaches a milestone in its pivotal clinical study of the Preserflo MicroShunt.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| PRIMA Retinal Implant Launched in EU | 22 Jul 2026 | 00:05:38 | |
A retinal implant system allowing patients with GA to regain some functional central vision vison is approved in Europe; Bausch + Lomb launches a new preloaded IOL delivery system in the US; and we review recent advancements and milestones in the development of novel ophthalmic treatments.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Tarsus Buys Investigational Ocular Antiseptic | 15 Jul 2026 | 00:05:46 | |
Tarsus acquires the maker of an investigational ocular antiseptic; Alcon and RxSight partner to jointly develop adjustable PCIOLs; and the FDA will hold a meeting to discuss Sydnexis’ investigational low-dose atropine therapy for myopia.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Viridian Executive Discusses FDA Approval of New TED Therapy | 01 Jul 2026 | 00:14:15 | |
An executive from Viridian discusses the FDA approval of Lumvoa for thyroid eye disease (TED); a biosimilar referencing Lucentis is relaunched in the US; and Lumibird introduces a wireless integrated laser-indirect-ophthalmoscope.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Ocular Updates Plans for Axpaxli NDA for Wet AMD | 24 Jun 2026 | 00:06:37 | |
Ocular Therapeutix provides a key update on its NDA plans for wet AMD drug candidate Axpaxli; Thea US launches a first-of-its-kind eye gel for glaucoma; and there were several recent milestones reached in the clinical development of novel drugs for a variety of ocular conditions.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Tecnis PureSee IOL Fully Launched in the US | 17 Jun 2026 | 00:06:44 | |
Johnson & Johnson expands the availability of its latest Tecnis lens; Bayer completes its acquisition of Perfuse Therapeutics, expanding its presence in ophthalmology; and ophthalmic leaders discuss how to navigate the current regulatory environment of the FDA.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Study Examines Semaglutide and Wet AMD Risk | 10 Jun 2026 | 00:04:39 | |
An international study examines the link between a popular weight loss medication and wet AMD risk; Heidelberg receives FDA clearance for a Spectralis software upgrade; and Bausch + Lomb launches its latest over-the-counter dry eye relief product in the US.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Oculis Announces Phase 3 Results for DME Eye Drops | 03 Jun 2026 | 00:04:51 | |
Oculis Releases phase 3 data for its investigational eye drop for DME; Rayner expands its surgical offerings with the launch of a new OVD; and a biosimilar referencing Eylea is launched in Europe.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Outlook Wins Appeal for Wet AMD Drug Candidate Lytenava | 27 May 2026 | 00:04:31 | |
Outlook Therapeutics takes a major step forward in its plan to gain approval for wet AMD drug Lytenava; the first commercial FLIGHT procedures using the ViaLuxe Laser System are performed in Europe; and Oculus introduces a new AI-assisted tool designed to help clinicians evaluate MGD using meibography images.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Next-Generation FSYX Goggles Approved for Glaucoma | 20 May 2026 | 00:08:06 | |
The FDA approves wireless pressure-modulating goggles for at-home glaucoma treatment; Bausch + Lomb launches a new PreserVision AREDS eye vitamin formation; and an Executive Strategic Advisor discusses the regulation environment for communication in eye care.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Future of Posterior Therapeutics | 13 May 2026 | 00:10:58 | |
Leading ophthalmologists join us to discusses the hottest topics in the posterior segment treatment landscape.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Bayer Acquires Perfuse in $2.45 Billion Deal | 06 May 2026 | 00:06:50 | |
Bayer expands ophthalmology pipeline with acquisiton of Perfuse Therapeutics; Viridian announces new phase 3 data for its investigational subcutaneous injection for chronic thyroid eye disease; and Steven Dell, MD discusses the impact of declining reimbursement could on ophthalmic practices.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| How Ophthalmology Strategics are Rewriting the Playbook | 29 Apr 2026 | 00:06:10 | |
Ophthalmic executives discuss strategies to scale and grow in today’s economic and regulatory environments.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Glaukos Issued J-Code for Recently Launched Epioxa | 22 Apr 2026 | 00:05:07 | |
Glaukos commercially launches its topical drug therapy for keratoconus; BVI’s next-generation phaco-vitrectomy surgical system receives CE Mark; and the ASCRS Executive Director recaps the 2nd annual Sightline meeting.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Breaking News from the ASCRS Meeting in Washington DC | 15 Apr 2026 | 00:13:43 | |
Eyewire reports on new products and breaking news live from the American Society of Cataract and Refractive Surgery meeting in Washington DC.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| More than 3 Million Bottles of Eye Drops Recalled | 08 Apr 2026 | 00:04:41 | |
A major recall is announced for several store-brand OTC eye drops; the FDA extends dosing intervals for Eylea HD in patients with Wet AMD and DME; and Bausch + Lomb launches its second full range of vision IOL in Europe.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Biogen Enters GA Treatment Market After Major Acquisition | 01 Apr 2026 | 00:05:44 | |
Pharma giant Biogen announces its intention to acquire Apellis in a multi-billion dollar deal; a recently approved first-of-its-kind presbyopia drop is commercially launched; and Kodiak Sciences releases phase 3 data for its diabetic retinopathy drug candidate.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Interview with ASCRS Executive Director Steve Speares | 25 Mar 2026 | 00:11:41 | |
The Executive Director of The American Society of Cataract & Refractive Surgery (ASCRS) previews the upcoming annual meeting and discusses the most pressing issues facing ophthalmology.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Alcon and Lensar Call Off Merger | 18 Mar 2026 | 00:06:22 | |
Alcon and Lensar provide a major update to their proposed merger; the latest IOL on Johnson & Johnson’s Tecnis platform receives FDA approval; and the FDA issues another CRL to Aldeyra Therapeutics for its investigational dry eye drug reproxalap.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| FDA Agrees to Review Phentolamine for Presbyopia | 04 Mar 2026 | 00:11:31 | |
The FDA agrees to review a presbyopia drop designed to modulate pupil dynamics; a new endocapsular device receives clearance in Europe; and Rayner makes an acquisition to expands its cataract surgery portfolio.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Zeiss Launches App to Improve Workflow | 25 Feb 2026 | 00:03:53 | |
Zeiss releases a software app that aims to address longstanding challenges in ophthalmic care; Oertli launches its new surgical platform, the OS 4 Up, in Europe; and Harrow introduces direct-to-prescriber cash-pay kits for ophthalmic branded medications.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Ocular Releases Phase 3 Data for Wet AMD Candidate Axpaxli | 18 Feb 2026 | 00:06:02 | |
Ocular Therapeutix releases its long-awaited SOL-1 phase 3 data for wet AMD drug candidate Axpaxli; Nordic Pharma expands the availability of its novel dry eye therapy Lacrifill; and Alcon launches the only multifocal toric contact lens featuring Water Gradient Technology.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Study: Metformin May Lower AMD Progression | 11 Feb 2026 | 00:05:06 | |
New research reveals that a popular diabetes treatment may lower the risk of AMD progression; a study examines the performance of large language models on specialty ophthalmology examinations; and a new doctor-led alliance that aims to support private practice optometrists has officially launched.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| First Dual-Agent Eye Drop for Presbyopia Approved | 04 Feb 2026 | 00:07:25 | |
The FDA approves the first dual-agent eye drop for presbyopia; Rayner launches a personalized, AI-powered patient education platform; and new study examines the link between sleep positioning and eye pressure.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| FDA Approves Label Supplement for iDose TR | 28 Jan 2026 | 00:05:37 | |
The FDA approves a key label supplement for Glaukos’ iDoseTR; Nidek announces the European launch of a new open-field refraction system; and there have been several leadership changes announced during the first month of 2026.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Rayner Launches New Phaco System | 21 Jan 2026 | 00:04:14 | |
Rayner launches a new phaco system in the US; Eylea 8 mg is approved for a third indication in Europe; and Nanodropper announces a consolidation plan to expand its offerings under a new name.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Moorfields Researchers Reveal Promising Treatment for Hypotony | 14 Jan 2026 | 00:10:22 | |
New research may provide hope for patients with a rare vision-threatening condition; the first daily disposable soft contact lens using EDOF technology for presbyopia is cleared in the US; and there several advancements made in the clinical development of treatment candidates for retinal diseases.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Staar Terminates Merger with Alcon | 07 Jan 2026 | 00:11:35 | |
Shareholders vote on Alcon’s blockbuster acquisition proposal for Staar Surgical; the FDA responds to Outlook’s latest BLA submission for wet AMD drug Lytenava; and the FDA approves an interchangeable biosimilar to Lucentis.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| 2025 Year in Review - Part 2 | 31 Dec 2025 | 00:08:45 | |
Highlights from the last 6 months of 2025 include advancements of emerging technologies in glaucoma, the first pharmacologic treatment for myopia in Europe, the expansion of labels for anti-VEGF treatments, and the release of the DEWS III report exploring the diagnosis and management of dry eye disease.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| 2025 Year in Review - Part 1 | 24 Dec 2025 | 00:09:37 | |
There were several advancements made during the first 6 months of 2025, including the first FDA approval for neurodegenerative disease MacTel; the approval of a first-of-its-kind drug for dry eye disease; advancements in premium IOLs; the approval of an excimer laser platform, and the launch of a new presbyopia drop.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Update on Reproxalap PDUFA Timing | 17 Dec 2025 | 00:08:51 | |
Aldeyra provides an update on the timing of its dry eye disease treatment candidate reproxalap; Ocular Therapeutix pursues an accelerated NDA pathway for wet AMD therapy Axpaxli; and companies with late-stage drug candidates announce FDA submission plans.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| New Glaucoma Technologies Advance in Clinical Development | 10 Dec 2025 | 00:05:07 | |
Companies with plans to commercialize glaucoma technologies in the US reach clinical milestones; Haag-Streit announces the global launch of a new Indirect ROP Laser Module; and EyeYon Medical gets approval to initiate a US clinical study of its EndoArt corneal implant.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Eylea HD Approved for RVO and Extended Dosing | 03 Dec 2025 | 00:05:00 | |
Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Leaders Discuss Emerging Technologies in Glaucoma | 26 Nov 2025 | 00:13:27 | |
Several new technologies are emerging that aim to transform the way glaucoma is treated and managed. Many of these technologies are now available to patients outside of the United States, with the goal of expanding availability to the US and beyond.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Live Coverage of B+L Investor Day | 18 Nov 2025 | 00:06:59 | |
Bausch + Lomb outlines a strategic path to innovation and growth at its Investor Day; Apellis reports new 5-year data examining Syfovre and GA progression; and two global organizations for restoring sight merge.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Ryjunea Approved in the UK for Myopia | 12 Nov 2025 | 00:05:17 | |
Sydnexis receives another regulatory approval for its childhood myopia eye drop; Eli Lilly makes two major investments in ophthalmology; and Nanoscope reports new long-term data for its intravitreal optogenetic therapy for RP.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
| Ophthalmic Executives Provide Company Updates (Part 2 of 2) | 05 Nov 2025 | 00:15:18 | |
Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast.
Learn more about your ad choices. Visit megaphone.fm/adchoices | |||
© My Podcast Data · Projet indépendant · Données issues d'Apple & Spotify